

# Curriculum Vitae

## Alexandra Schäfer, Ph.D.

### PERSONAL:

Department of Epidemiology  
Gillings School of Global Public Health  
University of North Carolina at Chapel Hill  
McGavran-Greenberg Hall, CB# 7435  
Chapel Hill, North Carolina 27599-7435  
Phone: 919-966-3881  
[aschaefer@email.unc.edu](mailto:aschaefer@email.unc.edu)

### EDUCATION:

- 2003            Ph.D. in Virology, Friedrich-Alexander University Erlangen-Nuremberg, Germany
- 1999            M.S. in Biology, Johannes Gutenberg University Mainz, Germany
- 1996            B.S. in Biology, Johannes Gutenberg University Mainz, Germany

### PROFESSIONAL EXPERIENCE:

- 2021 - Present    **Assistant Professor (Research Track)** University of North Carolina at Chapel Hill,  
Gillings School of Global Public Health, Department of Epidemiology
- 2015 - Present    **Guest Researcher** Rocky Mountain Laboratories (RML), NIAID, NIH, Hamilton, MT
- 2013 - 2021      **Research Associate** University of North Carolina at Chapel Hill,  
Gillings School of Global Public Health, Department of Epidemiology
- 2007 - 2013      **Postdoctoral Research Associate** University of North Carolina at Chapel Hill, Chapel  
Hill, NC
- 2003 - 2007      **Postdoctoral Research Fellow**, Duke University Medical Center, Durham, NC,  
Department of Molecular Genetics and Microbiology and Howard Hughes Medical  
Institute (HHMI)

### HONORS:

- 2012            Invitation as 'Early Career Investigator', Nature Medicine: Herrenhausen Symposium on  
Viral Pathogenesis; Kloster Seeon, Seeon, Germany
- 2006            Young Investigator Travel Award, 13<sup>th</sup> Conference on Retroviruses and Opportunistic  
Infections, Denver CO
- 1998            Stipend for excellent performance as a graduate student, Johannes-Gutenberg University  
Mainz, Germany

### MEMBERSHIPS

- 2018 – present    International Mammalian Genome Society (IMGS)

2007 – present American Society for Virology (ASV)

2003 – present American Society for Microbiology (ASM)

2000 – present German Society for Virology (Gesellschaft für Virologie, GfV)

## BIBLIOGRAPHY

### \* *Equal Contribution*

1. Lee J, Stewart C, **Schäfer A**, Leaf EM, Park Y-J, Asarnow D, Powers JM, Treichel C, Corti D, Baric RS, King NP, Veesler D. A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines. *Nat Comm*. 2024. 15(1):5496
2. Martinez DR, Moreira FR, Catanzaro NJ, Diefenbacher MV, Zweigart MR, Gully KL, De la Cruz G, Brown AJ, Adams LE, Yount B, Baric TJ, Mallory ML, Conrad H, May SR, Dong S, Scobey DT, Nguyen C, Montgomery SA, Perry J, Babusis D, Barrett KT, Nguyen A-H, Kalla R, Bannister R, , Feng JY, Cihlar T, Baric RS, Mackman RL, Bilello JP\*, **Schäfer A\***, Sheahan TP\*. The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses. *Sci Transl Med*. 2024. 16(748):eadj4504.
3. Leist SR\*, **Schäfer A\***, Risemberg EL\*, Bell TA, Hock P, Zweigart MR, Linnertz CL, Miller DR, Shaw GD, Pardo Manuel de Villena F, Ferris MT, Valdar W, Baric RS. Sarbecovirus disease susceptibility is conserved across viral and host models. *Virus Res*. 2024: 346:199399.
4. **Schäfer A**, Marzi A, Furuyama W, Catanzaro NJ, Nguyen C, Haddock E, Feldmann F, Meade-White K, Thomas T, Gully KL, Leist SR, Hock P, Bell TA, Hubbard ML, De la Cruz GE, Martinez DR, Shaw GD, Miller DR, Vernon MJ, Graham RL, Cowley DO, Montgomery SA, Schughart K, Pardo Manuel de Villena F, Ferris MT, Feldmann H, Baric RS. Mapping susceptibility alleles for Ebola virus disease in mice. *Cell Rep*. 2024; 43(5):114127.
5. **Schäfer A**, Gralinski LE, Leist SR, Hampton BK, Mooney MA, Jensen KL, Graham RL, Agnithothram S, Jeng S, Chamberlin S, Bell TA, Scobey DT, Linnertz CL, VanBlargan LA, Thckray LB, Kock P, Miller DR, Shaw GD, Diamond MS, Pardo Manuel de Villena F, McWeeney SK, Heise MT, Menachery VD, Ferris MT, Baric RS. Genetic loci regulate Sarbecovirus pathogenesis: A comparison across mice and humans. *Virus Res.*, 2024; 344:199357.
6. Dillard J, Taft-Benz S, Knight A, Anderson E, Pressey K, Parotti B, Martinez S, Diaz J, Sarkar S, Madden E, De la Cruz G, Adams L, Dinnon K, Leist S, Martinez D, **Schäfer A**, Powers J, Yount B, Castillo I, Morales N, Burdick J, Evangelista MK, Ralph L., Pnkow N, Linnertz C, Lakshmanane P, Montgomery S, Ferris MT, Baric RS, Baxter V, Heise MT. Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus. *Nat Commun*. 2024; 15(1):3738.
7. Montoya B, Melo-Silva C, Tang L, Kafle S, Lidskiy P, Bajusz C, Vadovics M, Muramatsu H, Abraham E, Lipinszki Z, Chatterje D, Scher G, Benitz J, Sung MHM, Tam YK, Catanzaro NJ, **Schäfer A**, Andino R, Baric RS, Martinez DR, Pardi N, Sigal LJ. mRNA-LNP vaccine-induced CD8<sup>+</sup> T-cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies. *Mol Ther*. 2024; doi:10.1016/j.ymthe.2024.04.019
8. Eisfeld AJ, Anderson LN, Fan S, Walters KB, Halfmann PJ, Westhoff Smith D, Thackray LB, Tan Q, Sims AC, Menachery DV, **Schäfer A**, Sheahan TP, Cockrell AS, Stratton KG, Webb-Robertson BM, Kyle JE, Burnum-Johnson KE, Kim YM, Nicora CD, Peralta Z, N'jai AU, Sahr F, van Bakel H, Diamond MS, Baric RS, Metz TO, Smith RD, Kawaoka Y, Waters KM. A compendium of multi-omics data illuminating host responses to lethal human virus infections. *Sci Data*, 2024;11(1):328.

9. Graham JB, Swarts JL, Leist SR, **Schäfer A**, Bell TA, Hock P, Farrington J, Shaw GD, Ferris MT, Pardo-Manuel de Villena F, Baric RS, Lund JM. Unique immune profiles in collaborative cross mice linked to survival and viral clearance upon infection. *iScience*, 2024; 27(3):109103.
10. **Schäfer A**, Martinez DR. “Training immunity” against nosocomial infections. *Sci Immunol.*, 2023; 8(89):ead15685
11. Martinez DR\*, **Schäfer A\***, Gavitt TD\*, Mallory ML, Lee E, Catanzaro NJ, Chen H, Gully KL, Scobey DT, Korategere P, Brown A, Smith L, Parks R, Barr M, Newman A, Bowman C, Mansouri K, Edwards RJ, Baric RS, Haynes BF, Saunders KO. Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice. *Cell Rep.*, 2023;42(10):113248
12. Clancy CS, Smart G, Rhoderick JF, O’Donnell KO, Rosenke R, **Schäfer A**, Marzi A. Establishing a mouse model for sexual transmission and male reproductive tract persistence of Ebola virus. 2023. *J Infect Dis.*, 2023; 228(Suppl 7): S554–S558
13. Kapingidza AB, Marston DJ, Harris C, Wrapp D, Winters K, Mielke D, Xiaozhi L, Yin Q, Foulger A, Parks R, Barr M, Newman A, **Schäfer A**, Eaton A, Flores JM, Harner A, Catanzaro NJ Jr, Mallory ML, Mattocks MD, Beverly C, Rhodes B, Mansouri K, Van Itallie E, Vure P, Dunn B, Keyes T, Stanfield-Oakley S, Woods CW, Petzold EA, Walter EB, Wiehe K, Edwards RJ, Montefiori DC, Ferrari G, Baric R, Cain DW, Saunders KO, Haynes BF, Azoitei ML. Engineered immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes. *Nat Commun.*, 2023; 14(1):7897
14. Hou YJ, Chiba S, Leist SR, Meganck RM, Martinez DR, **Schäfer A**, Catanzaro NJ, Sontake V, West A, Edwards CE, Yount B, Lee RE, Gallant SC, Zost SJ, Powers J, Adams L, Kong EF, Mattocks M, Tata A, Randell SH, Tata PR, Halfmann P, Crowe JE Jr, Kawaoka Y, Baric RS. Host range, transmissibility and antigenicity of a pangolin coronavirus. *Nat Microbiol.*, 2023; (10):1820-1833
15. Tse LV, Hou YJ, McFadden E, Lee RE, Scobey TD, Leist SR, Martinez DR, Meganck RM, **Schäfer A**, Yount BL, Mascenik T, Powers JM, Randell SH, Zhang Y, Wang L, Mascola J, McLellan JS, Baric RS. A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus. *Sci Transl Med.*, 2023;15(715):eadg5567
16. Guseman AJ, Rennick LJ, Nambulli S, Roy CN, Martinez DR, Yang DT, Bhinderwala F, Vergara S, **Schaefer A**, Baric RS, Ambrose Z, Duprex WP, Gronenborn AM. Targeting spike glycans to inhibit SARS-CoV-2 viral entry. *Proc Natl Acad Sci U S A*, 2023; 120(38):e2301518120.
17. Cable J, Denison MR, Kielian M, Jackson WT, Bartenschlager R, Ahola T, Mukhopadhyay S, Fremont DH, Kuhn RJ, Shannon A, Frazier MN, Yuen KY, Coyne CB, Wolthers KC, Ming GL, Guenther CS, Moshiri J, Best SM, Schoggins JW, Jurado KA, Ebel GD, **Schäfer A**, Ng LFP, Kikkert M, Sette A, Harris E, Wing PAC, Eggenberger J, Krishnamurthy SR, Mah MG, Meganck RM, Chung D, Maurer-Stroh S, Andino R, Korber B, Perlman S, Shi PY, Bárcena M, Aicher SM, Vu MN, Kenney DJ, Lindenbach BD, Nishida Y, Rénia L, Williams EP. Positive-strand RNA viruses – a Keystone Symposia report. *Ann N Y Acad Sci*, 2023;1521(1):46
18. Adams LE, Leist SR, Dinno KH 3rd, West A, Gully KL, Anderson EJ, Loomer JF, Madden EA, Powers JM, **Schäfer A**, Sarkar S, Castillo IN, Maron JS, McNamara RP, Bertera HL, Zweigert MR, Higgins JS, Hampton BK, Premkumar L, Alter G, Montgomery SA, Baxter VK, Heise MT, Baric RS. Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. *Cell Reports*, 2023; 42(4):112326
19. Zhou P, Song G, Liu H, Yuan M, He WT, Beutler N, Zhu X, Tse LV, Martinez DR, **Schäfer A**, Anzanello F, Yong P, Peng L, Dueker K, Musharrafieh R, Callaghan S, Capozzola T, Limbo O, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Jardine JG, Safonova Y, Briney B, Rogers TF, Wilson IA, Baric RS, Gralinski LE, Burton DR, Andrabi R. Broadly neutralizing anti-S2

antibodies protect against all three human betacoronaviruses that cause deadly disease. *Immunity*, 2023; 56(3):669

20. Snouwaert JN, Jania LA, Nguyen T, Martinez DR, **Schäfer A**, Catanzaro NJ, Gully KL, Baric RS, Heise M, Ferris MT, Anderson E, Pressey K, Dillard JA, Taft-Benz S, Baxter VK, Ting JP, Koller BH. Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements. *PLoS Pathog.* 2023; 19(2):e1011168
21. Dagotto G, Ventura JD, Martinez DR, Anioke T, Chung BS, Siamatu M, Barrett J, Miller J, **Schäfer A**, Yu J, Tostanoski LH, Wagh K, Baric RS, Korber B, Barouch DH. Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex. *NPJ Vaccine*, 2022; 7(1):125
22. Chen C\*, Saville JW\*, Marti MM\*, **Schäfer A\***, Cheng MH\*, Mannar D, Zhu X, Berezuk AM, Banerjee A, Sobolewski MD, Kim A, Treat BR, Da Silva Castanha PM, Enick N, McCormick KD, Liu X, Adams C, Hines MG, Sun Z, Chen W, Jacobs JL, Barratt-Boyes SM, Mellors JW, Baric RS, Bahar I, Dimitrov DS, Subramaniam S, Martinez DR, Li W. Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatropic human VH domains. *iScience*, 2022; 25(8):104798
23. Chang MR, Tomasovic L, Kuzmina NA, Ronk AJ, Byrne PO, Johnson R, Storm N, Olmedillas E, Hou YJ, **Schäfer A**, Leist SR, Tse LV, Ke H, Coherd C, Nguyen K, Kamkaew M, Honko A, Zhu Q, Alter G, Saphire EO, McLellan JS, Griffiths A, Baric RS, Bukreyev A, Marasco WA. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. *Nat Comm.*, 2022; 13(1):5814
24. Li D, Martinez DR, **Schäfer A**, Chen H, Barr M, Sutherland LL, Lee E, Parks R, Mielke D, Edwards W, Newman A, Bock KW, Minai M, Nagata BM, Gagne M, Douek DC, DeMarco CT, Denny TN, Oguin TH 3rd, Brown A, Rountree W, Wang Y, Mansouri K, Edwards RJ, Ferrari G, Sempowski GD, Eaton A, Tang J, Cain DW, Santra S, Pardi N, Weissman D, Tomai MA, Fox CB, Moore IN, Andersen H, Lewis MG, Golding H, Seder R, Khurana S, Baric RS, Montefiori DC, Saunders KO, Haynes BF. Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine. *Nat Commun.*, 2022; 13(1):6309
25. **Schäfer A**, Leist SR, Gralinski LE, Martinez DR, Winkler ES, Okuda K, Hawkins PE, Gully KL, Graham RL, Scobey DT, Bell TA, Hock P, Shaw GD, Loomer JF, Madden EA, Anderson E, Baxter VK, Taft-Benz SA, Zweigart MR, May SR, Dong S, Clark M, Miller DR, Lynch RM, Heise MT, Tisch R, Boucher RC, Pardo Manuel de Villena F, Montgomery SA, Diamond MS, Ferris MT, Baric RS. A multitrait locus regulates Sarbecovirus pathogenesis. *mBio*, 2022; 13(4):e0145422
26. Dinnon KH 3rd, Leist SR, Okuda K, Dang H, Fritch EJ, Gully KL, De la Cruz G, Evangelista MD, Asakura T, Gilmore RC, Hawkins P, Nakano S, West A, **Schäfer A**, Gralinski LE, Everman JL, Sajuthi SP, Zweigart MR, Dong S, McBride J, Cooley MR, Hines JB, Love MK, Groshong SD, VanSchoiack A, Phelan SJ, Liang Y, Hether T, Leon M, Zumwalt RE, Barton LM, Duval EJ, Mukhopadhyay S, Stroberg E, Borczuk A, Thorne LB, Sakthivel MK, Lee YZ, Hagood JS, Mock JR, Seibold MA, O'Neal WK, Montgomery SA, Boucher RC, Baric RS. SARS-CoV-2 infection produces chronic epithelial and immune cell dysfunction with fibrosis in mice. *Sci Transl Med.*, 2022; 14(664):eabo5070
27. Biering SB, Sarnik SA, Wang E, Zengel JR, Leist SR, **Schäfer A**, Sathyan V, Hawkins P, Okuda K, Tau C, Jangid AR, Duffy CV, Wei J, Gilmore RC, Alfajaro MM, Strine MS, Nguyenla X, Van Dis E, Catamura C, Yamashiro LH, Belk JA, Begeman A, Stark JC, Shon DJ, Fox DM, Ezzatpour S, Huang E, Olegario N, Rustagi A, Volmer AS, Livraghi-Butrico A, Wehri E, Behringer RR, Cheon DJ, Schaletzky J, Aguilar HC, Puschnik AS, Button B, Pinsky BA, Blish CA, Baric RS, O'Neal WK, Bertozzi CR, Wilen CB, Boucher RC, Carette JE, Stanley SA, Harris E, Konermann S, Hsu PD.

Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection. *Nat Genet.*, 2022; 54(8):1078

28. He WT, Musharrafieh R, Song G, Dueker K, Tse LV, Martinez DR, **Schäfer A**, Callaghan S, Yong P, Beutler N, Torres JL, Volk RM, Zhou P, Yuan M, Liu H, Anzanello F, Capozzola T, Parren M, Garcia E, Rawlings SA, Smith DM, Wilson IA, Safonova Y, Ward AB, Rogers TF, Baric RS, Gralinski LE, Burton DR, Andrabi R. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. *Nat Immunol.*, 2022; 23(6):960
29. Routhu NK, Gangadhara S, Lai L, Davis Gardner ME, Floyd K, Shiferaw A, Bartsch YC, Fischinger S, Khoury G, Rahman SA, Stampfer SD, **Schäfer A**, Jean SM, Wallace C, Stammen RL, Wood J, Cohen J, Nagy T, Parsons MS, Gralinski L, Kozlowski PA, Alter G, Suthar MS, Amara RR. A modified vaccinia Amkara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. *Sci. Immunol.*, 2022; 31:eabo0226
30. **Schäfer A\***, Martinez DR\*, Won JJ, Meganck RM, Moreira FR, Brown AJ, Gully KL, Zweigart MR, Conrad WS, May SR, Dong S, Kalla R, Chun K, Du Pont V, Babusis D, Tang J, Murakami E, Subramanian R, Barrett KT, Bleier BJ, Bannister R, Feng JY, Bilello JP, Cihlar T, Mackman RL, Montgomery SA, Baric RS, Sheahan TP. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. *Sci Transl Med.* 2022; 22:eabm3410
31. Martinez DR\*, **Schäfer A\***, Gobeil S\*, Li D\*, De la Cruz G, Parks R, Lu X, Barr M, Manne K, Mansouri K, Edwards RJ, Yount B, Anasti K, Montgomery SA, Shen S, Zhou T, Kwong PD, Graham BS, Mascola JR, Montefiori DC, Alam M, Sempowski GD, Wiehe K, Saunders KO, Acharya P, Haynes BF, Baric RS. A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice. *Sci Transl Med.* 2022; 14(629):eabj7125
32. Hsieh CL, Werner AP, Leist SR, Stevens LJ, Falconer E, Goldsmith JA, Chou CW, Abiona OM, West A, Westendorf K, Muthuraman K, Fritch EJ, Dinnon KH 3rd, **Schäfer A**, Denison MR, Chappell JD, Baric RS, Graham BS, Corbett KS, McLellan JS. Stabilized coronavirus spike stem elicits a broadly protective antibody. *Cell Reports* 2021; 37(5):109929
33. Tostanoski LH\*, Gralinski LE\*, Martinez DR\*, **Schaefer A\***, Mahrokhian SH, Li Z, Nampanya F, Wan H, Yu J, Chang A, Liu J, McMahan K, Dinnon 3rd KH, Leist SR, Baric RS, Barouch DH. Application of rhesus adenovirus vaccines to characterize correlates of protection in a mouse-adapted SARS-CoV-2 challenge model. *J Virol.* 2021; 95(23):e0097421
34. Walls AC, Miranda MC, **Schäfer A**, Pham MN, Greaney A, Arunachalam PS, Navarro M-J, Tortorici MA, Rogers K, O'Connor MA, Shirreff L, Ferrell DE, Bowen J, Brunette N, Kepl E, Zepeda SK1, Starr T, Hsieh C-L, Fiala B, Samuel Wrenn S, Pettie D, Claire Sydeman C, Kaitlin R. Sprouse KR, Johnson M, Blackstone A, Ravichandran R, Ogohara C, Carter L, Tilles SW, Rappuoli R, Leist RS, Martinez DR, Clark M, Tisch R, O'Hagan DT, Van Der Most R, Van Voorhis WC, Corti D, McLellan JS, Kleanthous H, Sheahan TP, Smith KD, Fuller DH, Villinger F, Bloom J, Pulendran B, Baric RS, King NP, Veesler D. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. *Cell* 2021; 184(21):5432-5447
35. Martinez DR\*, **Schäfer A\***, Leist SR, Gully K, Feng JY, Bunyan E, Porter DP, Cihlar T, Montgomery SA, Baric RS, Nussenzweig MC, Sheahan TP. Early therapy with remdesivir and antibody combinations improve COVID-19 disease in mice. *Cell Reports* 2021; 36(4):109450
36. Li D\*, Edwards RJ\*, Manne K\*, Martinez DR\*, **Schäfer A\***, Alam SM, Wiehe K, Lu X, Parks R, Sutherland LL, Oguin TH, McDanal C, Perez LG, Mansouri K, Gobeil SMC, Janowska K, Stalls V, Kopp M, Cai F, Lee E, Foulger A, Hernandez GE, Sanzone A, Tilahun K, Jiang C, Tse LV, Bock KW, Minai M, Nagata BM, Cronin K, Gee-Lai V, Deyton M, Barr M, Von Holle T, Macintyre AN, Stover E, Feldman J, Hauser BM, Caradonna TM, Scobey TD, Moody MA, Cain DW, DeMarco CT, Denny TN,

Woods CW, Petzold EW, Schmidt AG, Teng IT, Zhou T, Kwong PD, Mascola JR, Graham BS, Moore IN, Seder R, Andersen H, Lewis MG, Montefiori DC, Sempowski GD, Baric RS, Acharya P, Haynes BF, Saunders KO. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. *Cell* 2021; 184(16):4203-4219

37. Yamin R, Jones AT, Hoffmann H-H, **Schäfer A**, Kao KS, Francis RL, Sheahan TP, Baric RS, Rice CM, Ravetch JV, Bournazos S. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. *Nature* 2021; 599(7885):465-470
38. Martinez DR, **Schäfer A**, Leist SR, De la Cruz G, West A, Atochina-Vasserman EN, Parks R, Barr M, Li D, Yount B, Saunders KO, Weissman D, Haynes BF, Montgomery SA, Baric RS. Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice. *Science* 2021; 373(6557):991-998
39. DiPiazza AT, Leist SR, Abiona OM, Moliva JI, Werner A, Minai M, Nagata BM, Bock KW, Phung W, **Schäfer A**, Dinnon 3rd KH, Chang LA, Loomis RJ, Boyoglu-Barnum S, Alvarado GS, Sullivan NJ, Edwards DK, Morabito KM, Mascola JR, Carfi A, Corbett KS, Moore IN, Baric RS, Graham BS, Ruckwardt TJ. COVID-19 vaccine mRNA-1273 elicits a protective immune profile that is not associated with vaccine-enhanced disease. *Immunity* 2021; 54(8):1869-1882
40. Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, **Schäfer A**, Wall S, Wang N, Janowska K, Pilewski KA, Venkat R, Parks R, Manamela NP, Raju N, Fechter EF, Holt CM, Suryadevara N, Chen RE, Martinez DR, Nargi RS, Sutton RE, Ledgerwood JE, Graham BS, Diamond MS, Haynes BF, Acharya P, Carnahan RH, Crowe JE Jr, Baric RS, Morris L, McLellan JS, Georgiev IS. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. *Cell Rep Med*. 2021 May 21:100313. doi: 10.1016/j.xcrm.2021.100313.
41. **Schäfer A**, Mueksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Maison RM, Gazumyan A, Martinez DR, Baric RS, Robbiani DF, Hatzioannou T, Ravetch JV, Bieniasz PD, Bowen RA, Nussenzweig MC, Sheahan TP. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. *J Exp Med* 2021; 218 (3): e20201993
42. Graham JB, Swarts JL, Leist SR, **Schäfer A**, Menachery VD, Gralinski LE, Jeng S, Miller DR, Mooney MA, McWeeney SK, Ferris MT, de Villena FP, Heise MT, Baric RS, Lund JM. Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. *PLoS Pathogens* 2021; 17 (1): e1009287 doi: 10.1371/journal.ppat.1009287
43. Atyeo C, Slein MD, Fischinger S, Burke J, **Schäfer A**, Leist SR, Kuzmina NA, Mire C, Honko A, Johnson R, Storm N, Bennett M, Tong P, Zuo T, Lin J, Zuiani A, Linde C, Suscovich T, Wesemann DR, Griffiths A, Desjarlais JR, Juelg BD, Goudsmit J, Bukreyev A, Baric R, Alter G. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. *JCI Insight* 2021; 6 (1): 143129
44. Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH III, Liu H, Madden VJ, Krzystek HM, De C, White KK, **Schäfer A**, Zaman T, Leist SR, Grant PO, Gully K, Bluemling GR, Natchus MG, Askin FB, Painter G, Browne EP, Jones CD, Pickles RJ, Baric RS, Garcia JV. Acute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801. *Nature* 2021; 591: 451-457
45. Li W\*, **Schäfer A**\*, Liu X\*, Martinez DR\*, Chen C, Sun Z, Leist SR, Drelich A, Zhang D, Ura M, Berezuk A, Chittori S, Leopold K, Mannar D, Srivasta SS, Zhu X, Peterson EL, Tseng C-T, Mellors JW, Subramaniam S, Baric RS, Dimitrov, DS. Exceptionally potent in vivo neutralization of SARS-CoV-2 by a bivalent human antibody VH domain uniquely blocking ACE2. *Cell* 2020; 183 (2): 429-441

46. Li W\*, Drelich A\*, Martinez DR\*, Gralinski LE\*, Chen C\*, Sun Z\*, **Schäfer A\***, Leist SR, Liu X, Zhelev D, Zhang L, Peterson EC, Conrad A, Mellors JW, Tseng C-T, Baric RS, Dimitrov DS. Potent neutralization of SARS-CoV-2 in vitro and in two animal models by a human monoclonal antibody. *Proc Natl Acad Sci USA* 2020; 117 (47): 29832-29838
47. Leist SR\*, **Schäfer A\***, Martinez DR\*. Cell and animal models of SARS-CoV-2 pathogenesis and immunity. *Dis Model Mech* 2020; 13 (9): dmm046581
48. Leist SR, Dinnon III KH, **Schäfer A**, Tse LV, Okuda K, Hou YJ, West A, Edwards CE, Sanders W, Fritch EJ, Gully KL, Scobey T, Brown AJ, Sheahan TP, Moorman NJ, Boucher RC, Gralinski LE, Montgomery SA, Baric RS. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. *Cell* 2020; 183 (4): 1070-1085
49. Dinnon III KH, Leist SR, **Schäfer A**, Edwards CE, Martinez DR, Montgomery SA, West A, Yount Jr BL, Hou YJ, Adams LE, Gully KL, Brown AJ, Huang E, Bryant MD, Choong IC, Glenn JS, Gralinski LE, Sheahan TP, Baric RS. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures. *Nature* 2020; 586 (7830): 560-566
50. Walls AC, Fiala B, **Schäfer A**, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Guerriero K, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH 3rd, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veessler D, King NP. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. *Cell* 2020; 183 (5): 1367-1382
51. Pruijssers AJ, George AS, **Schäfer A**, Leist SR, Gralinski LE, Dinnon III KH, Yount BL, Agostini ML, Laura J. Stevens, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP. Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing SARS-CoV-2 RNA polymerase in mice. *Cell Reports* 2020; 32 (3): 107940
52. Sheahan TP, Sims AC, Leist SR, **Schäfer A**, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun* 2020; 11 (1): 222
53. Graham JB, Swarts JL, Menachery VD, Gralinski LE, **Schäfer A**, Plante KS, Morrison CR, Voss KM, Green R, Choonoo G, Jeng S, Miller DR, Mooney MA, McWeeney SK, Ferris MT, Pardo-Manuel de Villena F, Gale M, Heise MT, Baric RS, Lund JM. Immune predictors of mortality after ribonucleic acid virus infection. *J Infect Dis* 2020; 221 (6): 882-889
54. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, **Schäfer A**, Reidy JX, Trivette A, Nargi RS, Sutton RE, Naveenchandra S, Martinez DR, Williamson LE, Chen EC, Jones T, Day S, Myers L, Hassan AO, Kafai NM, Winkler ES, Fox JM, Shrihari S, Mueller BK, Meiler J, Chandrashekar A, Mercado NB, Steinhardt JJ, Ren K, Loo Y-M, Kallewaard NL, McCune BT, Keeler SP, Holtzman MJ, Barouch DH, Gralinski LE, Baric RS, Thackray LB, Diamond MS, Carnahan RH, Crowe Jr JE. Potently neutralizing and protective antibodies against SARS-CoV-2. *Nature* 2020; 584 (7821): 443-449
55. Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, **Schäfer A**, Dinnon KH III, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison M, Baric RS. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Sci*

56. Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH 3rd, Leist SR, **Schäfer A**, Nakajima N, Takahashi K, Lee RE, Mascenik TM, Graham R, Edwards CE, Tse LV, Okuda K, Markmann AJ, Bartelt L, de Silva A, Margolis DM, Boucher RC, Randell SH, Suzuki T, Gralinski LE, Kawaoka Y, Baric RS. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science* 2020; 370 (6523): 1464-1468 doi:10.1126/science.abe8499
57. Corbett KS, Edwards D, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, **Schäfer A**, Ziwawo CT, DiPiazza AT, Dinnon III KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Bahl K, Garcia-Dominguez D, Ma LZ, Renzi I, Kong W-P, Schmidt SD, Wang L, Zhang Y, Stevens LJ, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanam E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. *Nature* 2020; 586 (7830): 567-571
58. Sun W, Leist SR, McCroskery S, Liu Y, Slamanig S, Oliva J, Amanat F, **Schäfer A**, Dinnon KH 3rd, García-Sastre A, Krammer F, Baric RS, Palese P. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. *EBioMedicine* 2020; 62: 103132
59. Sun W, McCroskery S, Liu WC, Leist SR, Liu Y, Albrecht RA, Slamanig S, Oliva J, Amanat F, **Schäfer A**, Dinnon KH 3rd, Innis BL, García-Sastre A, Krammer F, Baric RS, Palese P. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. *Vaccines (Basel)* 2020; 8 (4): 771
60. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon III KH, Kato T, Lee R, Yount BL, Mascenik TM, Chen G, Tse LV, Leist SR, Gralinski LE, **Schäfer A**, Dang H, Gilmore R, Fulcher L, Livraghi-Butrico A, Nicely NI, Cameron M, Cameron C, Kelvin DJ, de Silva A, Bowman N, Zumwalt R, Martinez FJ, Salvatore SP, Borczuk A, Tata PR, Kimple A, Jaspers I, Randell SH, Boucher RC, Baric RS. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. *Cell* 2020; 182 (2): 429-446
61. Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, Chen RE, Winkler ES, Wessel AW, Case JB, Kashentseva E, McCune BT, Bailey AL, Zhao H, VanBlargan LA, Dai YN, Ma M, Adams LJ, Shrihari S, Danis JE, Gralinski LE, Hou YJ, **Schäfer A**, Kim AS, Keeler SP, Weiskopf D, Baric RS, Holtzman MJ, Fremont DH, Curiel DT, Diamond MS. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell* 2020; 183 (1): 169-184
62. Noll KE, Whitmore AC, West A, McCarthy MK, Morrison CR, Plante KS, Hampton BK, Kollmus H, Pilzner C, Leist SR, Gralinski LE, Menachery VD, **Schäfer A**, Miller D, Shaw G, Mooney M, McWeeney S, Pardo-Manuel de Villena F, Schughart K, Morrison TE, Baric RS, Ferris MT, Heise MT. Complex genetic architecture underlies regulation of Influenza-A-virus-specific antibody responses in the Collaborative Cross. *Cell Rep* 2020; 31 (4): 10758
63. van Doremalen N, **Schäfer A**, Menachery VD, Letko M, Bushmaker T, Fisher RJ, Figueroa DM, Hanley PW, Saturday G, Baric RS, Munster VJ. SARS-like coronavirus WIV1-CoV does not replicate in Egyptian Fruit bats (*Rousettus aegyptiacus*). *Viruses* 2018; 19; 10 (12): 10.3390/v10120727
64. Agnihothram S, Menachery VD, Yount BL, Lindesmith LC, Scobey TD, Whitmore AC, **Schäfer A**, Heise MT, Baric RS. Development of a broadly accessible VEE replicon particle vaccine platform. *J Virol* 2018; 92 (11): e00027-18



65. Menachery VD\*, **Schäfer A\***, Burnum-Johnson KE, Mitchell HM, Einfeld AJ, Sims AC, Walters KB, Nicora CD, Purvine SO, Casey CP, Monroe ME, Weitz KK, Stratton KG, Webb-Robertson B-JM, Gralinski LE, Metz TO, Smith RD, Waters KM, Kawaoka Y, Baric RS. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. *Proc Natl Acad Sci USA* 2018; 30; 115 (5): E1012-E1021
66. Gralinski L, Menachery VD, Beall A, Kocher J, Morgan AP, Plante J, Shostak C, Totura AL, **Schäfer A**, Pardo-Manuel de Villena F, Ferris MT, Baric RS. Allelic variation in the Toll-like receptor adaptor protein *Ticam2* contributes to SARS-Coronavirus pathogenesis in mice. *G3* 2017; 7 (6): 1653-1663
67. **Schäfer A**, Baric RS. Epigenetic landscape during Coronavirus infection. *Pathogens* 2017; 6 (1): 8 doi: 10.3390/pathogens6010008
68. McDermott JE, Mitchell HD, Gralinski LE, Einfeld AJ, Josset L, Bankhead A 3rd, Neumann G, Tilton SC, **Schäfer A**, Li C, Fan S, McWeeney S, Baric RS, Katze MG, Waters KM. The effect of inhibition of PP1 and TNF $\alpha$  signaling on pathogenesis of SARS coronavirus. *BMC Syst Biol* 2016; 10 (1): 93
69. Totura AL, Whitmore A, Agnihothram S, **Schäfer A**, Katze MG, Heise MT, Baric RS. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to Severe Acute Respiratory Syndrome Coronavirus infection. *MBio* 2015; 6 (3): e00638-15
70. **Schäfer A**, Baric RS, Ferris MT. System approaches to coronavirus pathogenesis. *Curr Opin Virol* 2014; 6: 61-69
71. Menachery VD, Einfeld AJ, **Schäfer A**, Josset L, Sims AC, Proll S, Fan S, Li C, Neumann G, Tilton SC, Chang J, Gralinski LE, Long CE, Green R, Williams CM, Matzke MM, Webb-Robertson B-JM, Shukula KM, Metz TO, Smith RD, Waters KM, Katze MG, Kawaoka Y, Baric RS. Pathogenic influenza and coronaviruses utilize similar and contrasting approaches to control the interferon stimulated gene response. *MBio* 2014; 5 (3): e01174-14
72. Matthews K, **Schäfer A**, Pham A, Frieman M. The SARS Coronavirus Papain Like Protease can inhibit IRF3 at a post activation step that requires deubiquitination activity. *J Virol* 2014; 11: 209
73. Sims AC, Tilton SC, Menachery VD, Gralinski LE, **Schäfer A**, Matzke MM, Webb-Robertson B-JM, Chang J, Luna ML, Long CE, Shukula AK, Bankhead III AR, Burkett SE, Zornetzer G, Kent Tseng C-T, Metz TO, Pickles R, McWeeney S, Smith RD, Katze MG, Waters KM, Baric RS. Release of SARS-CoV nuclear import block enhances host transcription in human lung cells. *J Virol* 2013; 87: 3885-902
74. Brooke CC, **Schäfer A**, Whitmore AC, Johnston RE. Early interaction with the host complement system determines disease outcome following Venezuelan equine encephalitis virus infection. *J Gen Virol* 2012; 93: 797-806
75. **Schäfer A**, Brooke CC, Whitmore AC, Johnston RE. The role of the blood-brain barrier during Venezuelan equine encephalitis virus CNS infection. *J Virol* 2011; 85: 10682-10690
76. **Schäfer A**, Whitmore AC, Konopka JL, Johnston RE. Replicon particles of Venezuelan equine encephalitis virus as a reductionist murine model for encephalitis. *J Virol* 2009; 83: 1045-1057
77. **Schäfer A**, Cai X, Bilello JP, Desrosiers RC, Cullen BR. Cloning and analysis of miRNAs encoded by the primate gamma-herpesvirus rhesus monkey rhadinovirus. *Virology* 2007; 364: 21-27
78. Cai X, **Schäfer A**, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N, Cullen BR. Epstein-Barr Virus microRNAs are evolutionarily conserved and differentially expressed in infected cells. *PLoS Pathogens* 2006; 2 (3): e23

79. Doehle BP, **Schäfer A**, Cullen BR. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. *Virology* 2005; 339: 281-8
80. Russell RA, Wiegand HL, Moore MD, **Schäfer A**, McClure MO, Cullen BR. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. *J Virol* 2005; 79: 8724-8731
81. Doehle BP, **Schäfer A**, Wiegand HL, Bogerd HP, Cullen BR. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. *J Virol* 2005; 79: 8201-8207
82. Dutko JA, **Schäfer A**, Kenny AE, Cullen BR, Curcio MJ. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. *Current Biology* 2005; 15: 661-666
83. **Schäfer A**, Bogerd HP, Cullen BR. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. *Virology* 2004; 328: 163-168
84. **Schäfer A**, Lengenfelder D, Grillhösl C, Wieser C, Fleckenstein B, Ensser A. The latency-associated nuclear antigen homolog of herpesvirus saimiri inhibits lytic virus replication. *J Virol* 2003; 77: 5911-5925

## TEACHING

- 2023 EPID 799, Guest Lecturer (Dr. Ralph Baric, Class Leader), “Viral Hemorrhagic Fever”.
- 2022 EPID 799, Guest Lecturer (Dr. Ralph Baric, Class Leader), “Viral Hemorrhagic Fever”.

## SERVICE

### Journal Peer Review

- 2023 The Lancet
- 2022 Science Translational Medicine, Nature Communications, Cell Reports, Proceedings of the National Academy of Sciences, mBio
- 2020 Lancet Global Health, Cell Reports Medicine, EBioMedicine, mSphere
- 2019 Scientific Reports
- 2018 Journal of Virology, Viruses
- 2016 Virology

### Grant Reviews

- 2024 Early Career Reviewer (ECR) Program at the Center of Scientific Review (CSR) at National Institutes of Health (NIH)
- 2023 French National Research Agency (ANR) – APPG-Generic call – 2023, Panel CE15 – Immunology, Infectiology, and Inflammation

- 2022 European Science Foundation – Science connect – Call for Junior and Senior Research Projects of the Research Foundation Flanders (FWO)
- 2021 Swiss National Science Foundation (SNF) national research program ‘Advancing 3R – Animals, research and society (NRP79)’ and SNF Advanced Grants
- 2021 Austrian Science Fund (FWF – Der Wissenschaftsfonds) funding initiative for ‘Urgent Funding SARS-CoV-2’
- 2020 German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung, BMBF) funding initiative for ‘Research on COVID-19 in the wake of the SARS-CoV-2 outbreak’